BCL2L1 and neoplasm: The MEK1/2 inhibitor binimetinib potentiated the activity of venetoclax and ABT-737 under conditions that mimic the CLL tumor microenvironment via downregulation of MCL-1 activity, BIM and BCL-xL expression109.